Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Hemoglobinopathies Market Research Report Information by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease and other Hb Variant Diseases), Treatment (Stem-cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, ACE inhibitors, Hydroxyurea), End User (Hospitals & Clinics, Diagnostics Laboratories and others) - Forecast till 2032


ID: MRFR/HC/6626-HCR | 90 Pages | Author: Kinjoll Dey| May 2024

Hemoglobinopathies Market Scenario



Hemoglobinopathies Market Size was valued at USD 6.31 billion in 2022. The Hemoglobinopathies Market industry is projected to grow from USD 6.48 Billion in 2023 to USD 9.95 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.20% during the forecast period (2023 - 2032).



Hemoglobinopathies is a group of blood disorders such as sickle cell disease, thalassemia, and many others. It is considered the most common inherited disease across the globe. Also, nowadays, hemoglobinopathies have become much more common in central and northern Europe, including Germany, due to immigration.

The rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering driver of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of the 229 countries affecting over 70% of births. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2015, the initial screening of newborns to identify sickle cell disease (SCD) along with other hemoglobin disorders such as, alpha (őĪ) and beta (ő≤) thalassemia have also gained significant attention in recent years due to the change in the US demographics.

Unhygienic and poor healthcare infrastructure are some of the factors attributing to increase in the base of the target population in low-income regions such as South-East Asia, Mediterranean basin, and African region which will drive the market growth over the forecast period. However, the lack of treatment and diagnosis awareness may hamper the growth of the hemoglobinopathies market during the forecast period.


A class of blood conditions known as hemoglobinopathies includes thalassemia, sickle cell disease, and many others. It is regarded as the most prevalent inherited disease in the world. Additionally, due to immigration, hemoglobinopathies are much more prevalent throughout central and northern parts of Europe, including Germany. The market is predicted to be driven by the increased prevalence of hemoglobin diseases such as thalassemia, Hb C, sickle cell anemia, and Hb E. The market is anticipated to expand due to the increasing incidence of diseases like sickle cell disease (SCD) and thalassemia and a robust product pipeline to receive medical care for hemoglobinopathies.


Lack of awareness, unmet needs in managing sickle cell disease and thalassemia, and the absence of a long-term solution are major contributors to the high frequency of hemoglobinopathies. During the projected period for hemoglobinopathies, there has been an increase in the creation and research for treatments, which has helped the market grow. In addition, several treatments are currently available, including hydroxyurea, ACE inhibitors, and monoclonal antibody drugs. Gene therapy and iron chelation therapy are two other treatments. Increased illness prevalence, new screening techniques, and innovative research and development initiatives are anticipated to drive the market share for hemoglobinopathies. Hemoglobinopathies are genetic diseases that parents pass on to their children. Mutations in the hemoglobin gene are the cause of hemoglobinopathies.


The two primary kinds of hemoglobinopathies are thalassemia and hemoglobin (Hb) variation, brought on by changes in the hemoglobin gene. The numerous hemoglobinopathies, such as beta thalassemia, sickle cell disease, and hemoglobin variation, cause numerous health issues. The health issues linked to the condition include vision blur, cardiac issues, decreased growth, gallstones, spleen enlargement, and stroke. The key driver of market expansion is the rise in disease prevalence.


Recent developments in gene editing technology might result in a treatment for hemoglobinopathies such as sickle cell disease and -thalassemia. Adenosine base editing may be more efficient for treating sickle cell disease and beta-thalassemia than other gene editing techniques like CRISPR/Cas9, according to a study conducted jointly by scientists from St Jude Children's Research Hospital in Tennessee and the Broad Institute of MIT and Harvard in Massachusetts. The scientists discovered that base editing produced more positive outcomes by comparing five alternative gene editing techniques in hematopoietic and progenitor stem cells using Cas9 nucleases or adenine base editors. To potentially give a universal treatment for the condition, the researchers looked to determine if fetal hemoglobin expression might be restored in post-natal red blood cells.



Hemoglobinopathies Market Segmentation

The global hemoglobinopathies market is segmented based on type, treatment, end users, and region.

The global market for hemoglobinopathies, by type, is segmented into thalassemia, sickle cell disease, and other Hb variants diseases. Thalassemia is further classified as alpha thalassemia and beta thalassemia. Based on treatment, the market is classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. The market by end user has been classified into hospitals and clinics, diagnostics laboratories, and others. The sickle cell disease segment is expected to hold the largest market share of the hemoglobinopathies market owing to the presence of strong product pipelines such as Lent Globin and rising prevalence of sickle cell disease. Also, based on treatment, the blood transfusion segment holds the largest market share owing to significant success rate and increasing adoption of this treatment option.

In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The hemoglobinopathies market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European hemoglobinopathies market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hemoglobinopathies market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemoglobinopathies market in the Middle East and Africa has been segmented into the Middle East and Africa.

Hemoglobinopathies Market Key Players



  • Sanofi

  • Sangamo Therapeutics, Inc.

  • Global Blood Therapeutics

  • Neusoft Medical Systems Co., Ltd

  • Bluebird Bio, Inc.

  • Emmaus Life Sciences Inc.

  • Prolong Pharmaceuticals

  • Celgene Corporation

  • Alnylam Pharmaceuticals

  • Gamida Cell

  • Acceleron Pharma

  • Mast Therapeutic

  • HemaQuest Pharmaceuticals

  • Invenux


News


WHO has announced the inaugural gathering of the subgroup for developing guidelines on hemoglobinopathies. The World Health Organization (WHO) is dedicated to ensuring healthy lives and promoting well-being for all people of all ages in every country. WHO seeks to give worldwide, evidence-based recommendations to enhance maternal and perinatal wellness through its distinctive normative function in health.




Regional Market Summary

Global Hemoglobinopathies Market Share (%), by Region, 2017  Hemoglobinopathies Market_Image

Sources: MRFR Analysis

The Americas dominated the global market for hemoglobinopathies owing to the rising geriatric population within the region. As per the data suggested by the American Society of Hematology approximately 70,000 to 100,000 Americans have sickle cell disease, the most common form of an inherited blood disorder.

As per the Centers for Disease Control and Prevention (CDC) in 2010, the US incidence estimate for sickle cell trait (based on information provided by 13 states) was 73.1 cases per 1,000 black newborns, 3.0 cases per 1,000 white newborns, and 2.2 cases per 1,000 Asian or Pacific Islander newborns. The incidence estimates for Hispanic ethnicity (within 13 states) was 6.9 cases per 1,000 Hispanic newborns.

The rising participation of market players is also strongly impacting the growth of the Americas hemoglobinopathies market. For instance, in 2018, in Europe, Sanofi launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), bringing a new treatment option to patients who previously had none. In the US, this treatment was approved by the FDA in February 2019.

According to the Centers for Disease Control and Prevention (CDC), SCD affects approximately 100,000 Americans, which occurs among about one out of every 365 black or African American births.

Asia-Pacific (APAC) is expected to represent a phenomenal market growth throughout the forecast period due to the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E.

On the other hand, the Middle East and Africa held the least share in the global hemoglobinopathies market due to the low economic development, especially within the African region.

Hemoglobinopathies Market Segmentation


Global Hemoglobinopathies Market, by Type





  • Thalassemia

    • Alpha Thalassemia

    • Beta Thalassemia



  • Sickle Cell Disease

  • Other Hb Variants Diseases



Global Hemoglobinopathies Market, by Treatment




  • Stem-Cell Transplantation

  • Blood Transfusions

  • Analgesics

  • Antibiotics

  • Ace Inhibitors

  • Hydroxyurea



Global Hemoglobinopathies Market, by End User   




  • Hospitals & Clinics

  • Diagnostics Laboratories

  • Others



Global Hemoglobinopathies Market, by Region




  • Americas


    • North America

      • US

      • Canada



    • Latin America






  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe






  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific






  • Middle East & Africa

    • Middle East

    • Africa





Intended Audience 



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers


Report Attribute/Metric Details
  Market Size   USD 9.95 Billion by 2032
  CAGR   7.20% (2023-2032)
  Base Year   2022
  Forecast Period   2032
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi, Sangamo Therapeutics Inc., Global Blood Therapeutics, Bluebird Bio Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Celgene Corporation, Alnylam Pharmaceuticals, Gamida Cell, Acceleron Pharma, Mast Therapeutic, HemaQuest Pharmaceuticals, and Invenux.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   The increasing prevalence of hemoglobin-related disorders


Frequently Asked Questions (FAQ) :

Global Hemoglobinopathies Market is projected to reach USD 9.95 billion by 2032.

Hemoglobinopathies Market is expected to exhibit a strong 7.20% CAGR over the forecast period from 2023 to 2032.

The increasing prevalence of hemoglobin-related disorders is the major driver for the market.

Lack of awareness among consumers and the presence of poor healthcare infrastructure in developing parts of the world are the key restraints on the market.

Leading players in the global hemoglobinopathies market include Sanofi, Emmaus Life Sciences, Gamida Cell, Invenux, Global Blood Therapeutics, Sangamo Therapeutics, Acceleron Pharma, Prolong Pharmaceuticals, and Bluebird Bio Inc., among others.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.